Stone prevention is achievable in community practice, research shows
Chicago A private practice setting is just as successful with stoneprevention as a larger academic setting, according to research presentedat the AUA annual meeting here yesterday. And, if treatment is needed later,a patient can be better counseled about appropriate options following anaccurate assessment of the natural progression of stones.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.